Company Overview

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

  • Name

    CSL Limited

  • CEO

    Dr. Paul F. McKenzie Ph.D.

  • Website

    www.csl.com.au

  • Sector

    Biotechnology

  • Year Founded

    1916

Profile

  • Market Cap

    A$147.16B

  • EV

    A$165.99B

  • Shares Out

    484.09M

  • Revenue

    $14.8B

  • Employees

    32,698

Margins

  • Gross

    52.06%

  • EBITDA

    31.2%

  • Operating

    26.32%

  • Pre-Tax

    22.8%

  • Net

    17.85%

  • FCF

    12.94%

Returns (5Yr Avg)

  • ROA

    10.96%

  • ROTA

    42.48%

  • ROE

    23.46%

  • ROCE

    17.42%

  • ROIC

    15.15%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    A$315.32

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $1,657M

  • Net Debt

    $10.53B

  • Debt/Equity

    0.63

  • EBIT/Interest

    8.15

Growth (CAGR)

  • Rev 3Yr

    12.81%

  • Rev 5Yr

    11.63%

  • Rev 10Yr

    10.74%

  • Dil EPS 3Yr

    1.51%

  • Dil EPS 5Yr

    5.22%

  • Dil EPS 10Yr

    7.31%

  • Rev Fwd 2Yr

    6.9%

  • EBITDA Fwd 2Yr

    12.99%

  • EPS Fwd 2Yr

    14.54%

  • EPS LT Growth Est

    13.1%

Dividends

  • Yield

  • Payout

    48.26%

  • DPS

    $2.64

  • DPS Growth 3Yr

    5.95%

  • DPS Growth 5Yr

    7.37%

  • DPS Growth 10Yr

    8.86%

  • DPS Growth Fwd 2Yr

    12.69%

ASX:CSL